Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furazolidone-based quadruple regimens for Helicobacter pylori eradication
IRCT20230202057305N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of furazolidone in Helicobacter pylori infection (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Drug side effects and Helicobacter pylori eradication rate. Started Apr 2023; status: completed.
02
Drugs
furazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20230202057305N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230202057305N1.